Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.
You may also be interested in...
Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.
Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.
Cephalon Submits Fentora sNDA For Chronic Pain
Application includes strengthened risk management plan to ensure appropriate patient use and dosing, a critical concern after deaths were reported following unapproved uses.